NQO1 induction mediated by photodynamic therapy synergizes with β-Lapachone-halogenated derivative against melanoma

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• Elevated NQO1 expression in tumors makes it a target for enzyme-directed cancer therapy.
• NQO1 is crucial in melanogenesis and linked to poor melanoma prognosis, suggesting it as a therapeutic target.
• The NQO1-activated anticancer drug β-Lapachone (β-Lap) has dose-limiting toxicities, necessitating safer alternatives.

Purpose of the Study:

• To evaluate a novel halogenated β-Lap derivative, PFB, as an NQO1-bioactivatable agent for melanoma.
• To investigate the potential of combining PFB with photodynamic therapy (PDT) for enhanced melanoma treatment.
• To explore strategies for upregulating NQO1 activity in cancer cells for combinatorial therapy.

Main Methods:

• Synthesized and characterized a halogenated β-Lap derivative (PFB) as an NQO1 substrate.
• Assessed the efficacy of PFB against melanoma cells, including metastatic-derived cell lines.
• Investigated the synergistic effect of combining PFB with PDT on melanoma cells, analyzing NQO1 expression modulation.

Main Results:

• PFB demonstrated potent tumor-selective anticancer activity and was more effective than β-Lap against metastatic melanoma cells.
• Photodynamic therapy (PDT) was shown to significantly upregulate NQO1 expression in melanoma cells.
• The combination of PFB and PDT exhibited synergistic cytotoxic effects on melanoma cells.

Conclusions:

• PFB is a promising NQO1-bioactivatable agent for melanoma treatment with improved safety and efficacy profiles.
• Combining PDT with PFB chemotherapy offers a synergistic therapeutic strategy for melanoma.
• This approach provides a strong rationale for developing modular NQO1-targeted photo-chemotherapies for melanoma.